Información de la revista
Vol. 2. Núm. S3.
Esclerosis sistémica
Páginas S20-S23 (Noviembre 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 2. Núm. S3.
Esclerosis sistémica
Páginas S20-S23 (Noviembre 2006)
Esclerosis sistémica
Acceso a texto completo
Afección renal en la esclerosis sistémica
Renal involvement in systemic sclerosis
Visitas
24064
Luis J. Jaraa,
Autor para correspondencia
luis_jara_quezada@hotmail.com

Correspondencia: Dr. L.J. Jara. División de Investigación. Hospital de Especialidades Dr. Antonio Fraga Mouret. Seris/zaachila, s/n. Colonia La Raza. C.P 02990 México DF. México.
, Antonio Barrerab
a División de Investigación. Hospital de Especialidades Dr. Antonio Fraga Mouret. Centro Médico La Raza. México D.F. México
b Instituto Mexicano del Seguro Social. Universidad Nacional Autónoma de México. México DF. México
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

La crisis renal es una de las complicaciones más graves de la esclerosis sistémica y se presenta en el 10% de los pacientes. Esta complicación se caracteriza por hipertensión maligna, hiperreninemia, azoemia, anemia hemolítica microangiótica e insuficiencia renal. En la patogenia de la afección renal, el principal mecanismo es el daño endotelial (engrosamiento de los vasos arteriales), hipoperfusión renal que conduce a hiperplasia del aparato yuxtaglomerular y liberación de renina. Las alteraciones histopatológicas en el riñón son similares a las observadas en otras formas de hipertensión maligna. La crisis renal, complicación anteriormente fatal, actualmente se trata con éxito mediante los inhibidores de la enzima de conversión de la angiotensina.

Palabras clave:
Crisis renal
Daño entotelial
Inhibidores de la enzima de conversión de la angiotensina

Renal crisis is one of the most severe complications of systemic sclerosis, and its frequency is 10%, and it is characterized by malignant hypertension, hyperreninemia, azotemia, microangiopathic hemolytic anemia, and renal failure. In the pathogenesis of renal affection, the main mechanism is the endothelial damage (thickness of arterial vessels), decrease of blood flow and hyperplasia of the yuxtaglomerular apparatus as well as release of renina. Pathological changes of scleroderma kidney are similar to those observed in other forms of malignant hypertension. Renal crisis was considered as fatal complications, however it is now successfully treated with angiotensin- converting enzyme inhibitors.

Key words:
Renal crisis
Endothelial damage
Angiotensin-converting enzyme inhibidors
El Texto completo está disponible en PDF
Bibliografía
[1.]
L. Lendonck, A. Ocmant, F. Roufosse, E. Cogan.
Predictive markers for development of severe organ involvement in patients with systemic sclerosis.
Ann N Y Acad Sci, 1051 (2005), pp. 455-464
[2.]
V.D. Steen, A. Syzd, J. Johnson, A. Greenberg, T.A. Medsger.
Kidney disease other than renal crisis in patients with diffuse scleroderma.
J Rheumatol, 32 (2005), pp. 649-655
[3.]
V. Steen.
Targeted therapy for systemic sclerosis.
Autoimmun Rev, 5 (2006), pp. 122-124
[4.]
E.R. Fisher, G.P. Rodnan.
Pathologic observations concerning renal involvement in progressive systemic sclerosis (PSS).
Arch Pathol Lab Med, 65 (1958), pp. 29-39
[5.]
V.D. Steen.
Scleroderma renal crisis.
Rheum Dis Clin North Am, 22 (1996), pp. 861-878
[6.]
L. Barba, I. Pawlowski, J. Brentiens, G.A. Andres.
Nephropathies in rheumatic diseases.
Human Pathol, 14 (1983), pp. 290-304
[7.]
D. Lapenas, G. Rodnan, T. Cavallo.
Immunopathology of the renal vascular lesion of progressive systemic sclerosis.
Am J Pathol, 91 (1978), pp. 243-256
[8.]
L. Sokoloff.
Some aspects of the pathology of collagen diseases.
Bull N Y Acad Med, 32 (1952), pp. 760-767
[9.]
P.J. Canon, M. Hassar, D.B. Case, et al.
The relationship of hypertension and renal failure in scleroderma to structural and functional abnormalities of the renal cortical circulation.
Medicine, 53 (1974), pp. 1-46
[10.]
V.D. Steen.
Scleroderma renal crisis.
Rheum Dis Clin North Am, 22 (1996), pp. 861-878
[11.]
J.F. Donohoe.
Scleroderma and the kidney.
Kidney Int, 41 (1992), pp. 462-477
[12.]
O.H. Gunduz, N. Fertig, M. Lucas, T.A. Medsger.
Systemic sclerosis with renalcrisis and pulmonary hypertension.
[13.]
V.D. Steen, J.P. Constantino, A.P. Shapiro, T.A. Medsger.
Outcome of renal crisis in systemic sclerosis.
Ann Intern Med, 113 (1990), pp. 352-357
[14.]
V.D. Steen.
Scleroderma renal crisis.
Rheum Dis Clin North Am, 29 (2003), pp. 315-333
[15.]
H. Mitchell, M. Bolster, E. LeRoy.
Scleroderma and related conditions.
Med Clin North Am, 81 (1997), pp. 129-146
[16.]
D. Helfrich, B. Banner, V. Steen, T.A. Medsger.
Normotensive renal failure in systemic sclerosis.
Arthritis Rheum, 32 (1989), pp. 1128-1134
[17.]
M. Satoh, M. Tokuhira, N. Hamma, M. Hirakata, M. Kuwana, M. Akizuki, et al.
Massive pericardial effusion in scleroderma.
Br J Rheumatol, 34 (1995), pp. 564-567
[18.]
M. Ehrenfeld, A. Licht, J. Stessman, L. Yanko, E. Rosenmann.
Post partum renal failure due to progressive systemic sclerosis treated with chronic hemodialysis.
Nephron, 18 (1977), pp. 175-181
[19.]
P. Challan-Belval, I. Nisand, P. Dellenbach, J.P. Dupeyron, J.L. Pasquali, D. Storck.
Scleroderma and pregnancy. New case and review of the literature.
Ann Med Interne (Paris), 135 (1984), pp. 435-439
[20.]
J.E. Gore, A.N. Brown.
Scleroderma renal crisis sine scleroderma in pregnancy: a case report.
Clin Exp Rheumatol, 24 (2006), pp. 87-88
[21.]
C.C. Mok, T.H. Kwan, L. Chow.
Scleroderma renal crisis sine scleroderma during pregnancy.
Scand J Rheumatol, 32 (2003), pp. 55-57
[22.]
B.A. Baethge, R.E. Wolf.
Successful pregnancy with scleroderma renal disease and pulmonary hypertension in a patient using angiotensin converting enzyme inhibitors.
Ann Rheum Dis, 48 (1989), pp. 776-778
[23.]
L.J. Jara, O. Vera-Lastra, M.C. Calleja.
Pulmonary-renal vasculitic disorders: differential diagnosis and management.
Curr Rheumatol Rep, 5 (2003), pp. 107-115
[24.]
E. Lally, S. Jimenez, S. Kaplan.
Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients.
Semin Arthritis Rheum, 18 (1988), pp. 1-13
[25.]
C.T. Derk, S.A. Jimenez.
Goodpasture-like syndrome induced by D-penicillamine in a patient with systemic sclerosis: report and review of the literature.
J Rheumatol, 30 (2003), pp. 1616-1620
[26.]
V.D. Steen, A.M. Thomas.
Long-term outcomes of scleroderma renal crisis.
Ann Intern Med, 133 (2000), pp. 600-603
[27.]
C.A. O’Callaghan.
Renal manifestations of systemic autoimmune diseases: diagnosis and therapy.
Best Pract Res Clin Rheumatol, 138 (2004), pp. 411-427
[28.]
Y. Chang, H. Spiera.
Renal transplantation in scleroderma.
Medicine, 78 (1999), pp. 382-385
[29.]
S. Lee, S. Lee, K. Sharma.
The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis.
Curr Rheumatol Rep, 6 (2004), pp. 141-148
[30.]
R. Shor, A. Halabe.
New trends in the treatment of scleroderma renal crisis.
Nephron, 92 (2002), pp. 716-718
[31.]
E.Y. Rhew, W.G. Barr.
Scleroderma renal crisis: new insights and developments.
Curr Rheumatol Rep, 6 (2004), pp. 129-136
Copyright © 2006. Elsevier España S.L. Barcelona
Idiomas
Reumatología Clínica
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?